Adebrelimab and Chemoradiotherapy in High-risk LANPC

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 23, 2024

Primary Completion Date

May 1, 2028

Study Completion Date

May 1, 2028

Conditions
Nasopharyngeal CarcinomaNasopharyngeal Cancer
Interventions
DRUG

Adebrelimab

"Drug: Adebrelimab Adebrelimab 1200mg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.~Other Names:~PD-L1 antibody~Drug: Gemcitabine Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.~Other Names:~GEM~Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation~Other Names:~DDP~Radiation: Intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.~Other Names:~IMRT"

Trial Locations (4)

361003

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

510000

RECRUITING

Nanfang Hospital, Southern Medical University, Guangzhou

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

610000

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
collaborator

Nanfang Hospital, Southern Medical University

OTHER

collaborator

West China Hospital

OTHER

collaborator

The First Affiliated Hospital of Xiamen University

OTHER

lead

Sun Yat-sen University

OTHER